We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Test Diagnoses High-Risk Childhood Brain Tumors

By LabMedica International staff writers
Posted on 14 Mar 2025
Print article
Image: The new test offers the possibility of more personalized treatment options for medulloblastoma (Photo courtesy of Adobe Stock)
Image: The new test offers the possibility of more personalized treatment options for medulloblastoma (Photo courtesy of Adobe Stock)

Medulloblastoma, which originates in the cerebellum, the rear part of the brain, is the most prevalent malignant brain tumor in children and is notoriously difficult to diagnose. Currently, identifying the most aggressive forms of this disease relies on advanced, costly tests available only in a few specialized labs worldwide. Due to the limitations of current diagnostic methods, all children diagnosed with medulloblastoma are treated the same, meaning those with less aggressive forms of the tumor undergo potentially unnecessary and toxic brain radiation and chemotherapy. This approach often results in lasting learning, physical, and emotional disabilities. Conversely, children with the most aggressive forms of the disease may not receive sufficient treatment to cure it. A new test has now been developed that can differentiate between high-risk cases of medulloblastoma, which require radiation therapy, and lower-risk cases that do not, offering the possibility of more personalized treatment options for children affected by this condition.

The new test, developed through a collaboration that included researchers from the University of British Columbia (Vancouver, BC, Canada), employs an antibody-based technique called immunohistochemistry, which is widely available in clinical labs around the world. To create the test, the researchers analyzed a range of data sets, including proteomics (which assesses overall protein expression in tumor tissues) and transcriptomics (which evaluates gene expression in tumor tissues). By using this approach, the team identified a protein named TPD52 that is highly expressed in the most aggressive forms of medulloblastoma. They then screened about 400 medulloblastoma samples for the presence of this protein. The results, published in Clinical Cancer Research, showed that tumors with detectable levels of TPD52 were significantly more likely to behave aggressively and relapse.

“By using a technique that is available in virtually all clinical labs, our new test has the potential to improve the diagnosis and future treatment of medulloblastoma for children in almost every corner of the planet,” said the study’s lead author Dr. Alberto Delaidelli, MD.

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.